UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 65

Sortiert nach

Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it?

CPT: pharmacometrics and systems pharmacology, 2024-04, Vol.13 (4), p.509-510

2024

Volltextzugriff (PDF)

Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access

Clinical pharmacology and therapeutics, 2024-06, Vol.115 (6), p.1204-1207

2024

Volltextzugriff (PDF)

Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models

Journal of chemical information and modeling, 2015-08, Vol.55 (8), p.1720-1738

2015

Volltextzugriff (PDF)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients

Pharmaceutics, 2023-05, Vol.15 (5), p.1438

2023

Volltextzugriff (PDF)

Pharmacokinetics of Doxycycline in Adults with Cystic Fibrosis

Antimicrobial Agents and Chemotherapy, 2012-01, Vol.56 (1), p.70-74

2012

Volltextzugriff (PDF)

Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19

Clinical pharmacology and therapeutics, 2022-06, Vol.111 (6), p.1324-1333

2022

Volltextzugriff (PDF)

Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)

Journal of cystic fibrosis, 2024-05, Vol.23 (3), p.566-572

2024

Volltextzugriff (PDF)

Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic Pseudomonas aeruginosa Lung Infection: Inhibition of NF-κB, Inflammasome Gene Expression, and Pro-IL-1β Biosynthesis

Antibiotics (Basel), 2021-08, Vol.10 (9), p.1043

2021

Volltextzugriff (PDF)

Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity

Chemistry : a European journal, 2021-09, Vol.27 (49), p.12702-12708

2021

Volltextzugriff (PDF)

Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration

Journal of cystic fibrosis, 2024-05, Vol.23 (3), p.519-523

2024

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis

Antimicrobial agents and chemotherapy, 2017-10, Vol.61 (10)

2017

Volltextzugriff (PDF)

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1

Antimicrobial agents and chemotherapy, 2022-03, Vol.66 (3), p.e0212521-e0212521

2022

Volltextzugriff (PDF)

Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series

Pharmacotherapy, 2023-04, Vol.43 (4), p.291-299

2023

Volltextzugriff (PDF)

Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer

Neuro-oncology (Charlottesville, Va.), 2021-10, Vol.23 (10), p.1656-1667

2021

Volltextzugriff (PDF)

Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis

Antimicrobial agents and chemotherapy, 2018-09, Vol.62 (9)

2018

Volltextzugriff (PDF)

Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment

American journal of respiratory cell and molecular biology, 2018-03, Vol.58 (3), p.310-319

2018

Volltextzugriff (PDF)

Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation

Antimicrobial agents and chemotherapy, 2017-08, Vol.61 (8)

2017

Volltextzugriff (PDF)

Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms

Scientific reports, 2019-11, Vol.9 (1), p.16905-14, Article 16905

2019

Volltextzugriff (PDF)

The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients

Pharmacotherapy, 2019-06, Vol.39 (6), p.718-723

2019

Volltextzugriff (PDF)

A novel phenylcyclohex‐1‐enecarbothioamide derivative inhibits CXCL8‐mediated chemotaxis through selective regulation of CXCR2‐mediated signalling

British journal of pharmacology, 2014-03, Vol.171 (6), p.1551-1565

2014

Volltextzugriff (PDF)

Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa

Journal of antimicrobial chemotherapy, 2016-01, Vol.71 (1), p.181-188

2016

Volltextzugriff (PDF)

Population Pharmacokinetics and Use of Monte Carlo Simulation To Evaluate Currently Recommended Dosing Regimens of Ciprofloxacin in Adult Patients with Cystic Fibrosis

Antimicrobial Agents and Chemotherapy, 2001-12, Vol.45 (12), p.3468-3473

2001

Volltextzugriff (PDF)

Stability and Antibacterial Activity of Cefepime during Continuous Infusion

Antimicrobial Agents and Chemotherapy, 2003-06, Vol.47 (6), p.1991-1994

2003

Volltextzugriff (PDF)

Estimation of Glomerular Filtration Rate by Using Serum Cystatin C and Serum Creatinine Concentrations in Patients with Human Immunodeficiency Virus

Pharmacotherapy, 2010-10, Vol.30 (10), p.1004-1010

2010

Volltextzugriff (PDF)

Transporters and their impact on drug disposition

The Annals of pharmacotherapy, 2005-06, Vol.39 (6), p.1097

2005

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(64)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(56)
Life Sciences & Biomedicine
(50)
Humans
(36)
Pharmacology & Pharmacy
(33)
Female
(17)
Male
(17)
Adult
(15)
Biological And Medical Sciences
(15)
Cystic Fibrosis
(15)
Medical Sciences
(15)
Microbiology
(14)
Pharmacology. Drug Treatments
(13)
Middle Aged
(12)
Cystic Fibrosis - Drug Therapy
(11)
Animals
(9)
Pharmacokinetics
(9)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(8)
Aged
(7)
Infectious Diseases
(7)
Mice
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it?

Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access

Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients

Pharmacokinetics of Doxycycline in Adults with Cystic Fibrosis

Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19

Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)

Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic Pseudomonas aeruginosa Lung Infection: Inhibition of NF-κB, Inflammasome Gene Expression, and Pro-IL-1β Biosynthesis

Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity

Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1

Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series

Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer

Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis

Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment

Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation

Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms

The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients

A novel phenylcyclohex‐1‐enecarbothioamide derivative inhibits CXCL8‐mediated chemotaxis through selective regulation of CXCR2‐mediated signalling

Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa

Population Pharmacokinetics and Use of Monte Carlo Simulation To Evaluate Currently Recommended Dosing Regimens of Ciprofloxacin in Adult Patients with Cystic Fibrosis

Stability and Antibacterial Activity of Cefepime during Continuous Infusion

Estimation of Glomerular Filtration Rate by Using Serum Cystatin C and Serum Creatinine Concentrations in Patients with Human Immunodeficiency Virus

Transporters and their impact on drug disposition

Suchergebnisse filtern